Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold

Joner, 2006, Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J Am Coll Cardiol, 48, 193, 10.1016/j.jacc.2006.03.042 Raber, 2012, Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study, Circulation, 125, 1110, 10.1161/CIRCULATIONAHA.111.058560 Iqbal, 2014, Bioresorbable scaffolds: rationale, current status, challenges, and future, Eur Heart J, 35, 765, 10.1093/eurheartj/eht542 Karanasos, 2014, OCT Assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold, J Am Coll Cardiol, 64, 2343, 10.1016/j.jacc.2014.09.029 Simsek, 2016, Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities, EuroIntervention, 11, 996 Onuma, 2013, Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial, J Am Coll Cardiol Intv, 6, 999, 10.1016/j.jcin.2013.05.017 Serruys, 2015, Lancet, 385, 43, 10.1016/S0140-6736(14)61455-0 Kimura, 2015, A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan, Eur Heart J, 36, 3332, 10.1093/eurheartj/ehv435 Wohrle, 2015, Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds, EuroIntervention, 11, 149, 10.4244/EIJY14M12_10 Capodanno, 2015, Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry, EuroIntervention, 10, 1144, 10.4244/EIJY14M07_11 Cutlip, 2007, Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, 115, 2344, 10.1161/CIRCULATIONAHA.106.685313 Hermiller, 2012, Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study, J Interv Cardiol, 25, 565, 10.1111/j.1540-8183.2012.00766.x Abizaid, 2015, The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled, EuroIntervention, 10, 1396, 10.4244/EIJV10I12A243 Kraak, 2015, Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry, EuroIntervention, 10, 1160, 10.4244/EIJY14M08_08 Ishibashi, 2015, Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients, EuroIntervention, 11, e1, 10.4244/EIJY14M09_08 Capodanno, 2015, What about the risk of thrombosis with bioresorbable scaffolds?, EuroIntervention, 11, V181, 10.4244/EIJV11SVA43 Everaert, 2015, Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands, Neth Heart J, 23, 161, 10.1007/s12471-015-0651-3 Tamburino, 2015, Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective, EuroIntervention, 11, 45, 10.4244/EIJY15M01_05 Karanasos, 2015, Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience, Circ Cardiovasc Interv, 8, 10.1161/CIRCINTERVENTIONS.114.002369 Kolandaivelu, 2011, Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings, Circulation, 123, 1400, 10.1161/CIRCULATIONAHA.110.003210 Okamura, 2011, First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography, EuroIntervention, 6, 1037, 10.4244/EIJV6I9A182 Tu, 2012, In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography, Int J Cardiovasc Imaging, 28, 1315, 10.1007/s10554-012-0016-6 Robaei, 2015, Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedural and 30-day outcomes at two Australian centres, Heart Lung Circ, 24, 854, 10.1016/j.hlc.2015.02.011